2023-04-19 11:34:20 ET
- Esperion ( NASDAQ: ESPR ) signed an agreement with Currax Pharmaceuticals which provides for all of Currax's 72 sales representatives to co-promote cholesterol lowering therapies Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) tablets.
- The company said the deal more than doubles the sales representatives for the drugs.
- "We believe this performance-based agreement that provides a more than doubling of our sales representatives will provide us with the opportunity to build on the significant momentum we’ve seen since the announcement of the positive results from our landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial," said Esperion's President and CEO Sheldon Koenig.
For further details see:
Esperion, Currax team up to co-promote cholesterol lowering drug Nexletol